BIO

Bio-Rad Laboratories, Inc.

Fundamental data last updated:October 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

 


VALUATION

P/E

49.90

Market Cap ($M USD)

$8.45B

Forward P/E

22.71

PEG

0.19

PRICE TO SALES

3.26

PRICE TO BOOK

1.23

EV / EBITDA

269.33

5-Year Average P/E

Free Cash Flow Yield

4.23%

DCF Value

$-212.42

Graham Number

$189.22

Price to FCF

23.65

EV to FCF

26.09

Earnings Yield

2.00%

FCF Yield

4.23%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

19.73%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$6.26

Next Year EPS Growth Estimate

$13.76

Next Year Revenue Growth Estimate

$2.89B

Return on Equity (ROE)

2.40%

FREE CASH FLOW

Operating Margin

9.25%

Debt-to-Equity

0.21

Piotroski F-Score

6

Altman Z-Score

3.29

Return on Invested Capital (ROIC)

2.70%

Current Ratio

3.21

Quick Ratio

3.21

Net Debt to EBITDA

25.17

Interest Coverage

4.86

Gross Profit margin

51.87%

FCF PER SHARE

$13.25

REVENUE PER SHARE

$96.07

Gainseekers Quantitative Analysis

Summary

Bio-Rad Laboratories, Inc. presents a perplexing valuation scenario. Despite a Forward P/E of 20.59, which suggests moderate growth expectations, the stock’s DCF value is alarmingly negative, indicating potential overvaluation. The Graham Number also suggests a disconnect between intrinsic value and market pricing. However, the Altman Z-score of 2.96 implies reasonable financial stability, while the Earnings Yield of 2.46% is lackluster, hinting at limited immediate returns. The market seems to be pricing in significant future growth, but the current fundamentals raise questions about execution risk.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, Bio-Rad is well-positioned to leverage AI and tech advancements. As healthcare increasingly integrates digital solutions, the company can capitalize on AI-driven diagnostics and data analytics. This adaptability is crucial for maintaining a competitive edge in a rapidly evolving sector.

The Bull Case

For value and GARP investors, Bio-Rad offers intriguing prospects. The company's ROIC of 2.7% and a Piotroski F-Score of 6 suggest efficient capital allocation and sound financial health. With a Free Cash Flow Yield of 5.20%, there's a narrative of strong cash generation potential. The operating margin of 9.25% underscores its pricing power, making it an attractive play for those betting on operational efficiency and market resilience.

The Bear Case

However, the bear case is hard to ignore. The EV to EBITDA ratio is a staggering 223.89, signaling extreme valuation concerns. Additionally, the stock's proximity to its 52-week high suggests technical overextension. The Earnings Surprise of -5.03% raises red flags about management's ability to meet market expectations. While debt levels are manageable, the high Price to Sales ratio of 2.65 indicates the market may be overestimating future revenue growth.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$321.67

Institutional Ownership %

1-Year Beta

1.06

Insider Buying % (6 Mo)

Distance to 52-Week High

9.81%

Distance to 52-Week Low

32.34%

EARNINGS SURPRISE %

-5.03%

50-DAY SMA

$277.50

200-DAY SMA

$293.50

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.